Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study - Kavanaugh, A; McInnes, I; Mease, P (Arthritis and rheumatism, 2009)
et al.